Pazopanib
VOTRIENT, pazopanib
Kinase Inhibitor
NADAC/unit
N/A
No Shortage
Tier 1: 18.8%
PA Req: 100.6%
6 Manufacturers
6 ANDAs
Pazopanib targets specific kinase enzymes involved in cancer cell growth and proliferation.
Market Intelligence
2023-12-20 Class III Recall: Siegfried Barbera, SL
Generic Manufacturers
APOTEX INCEUGIA PHARMA SPECIALITIES LTDNOVARTIS PHARMACEUTICALS CORPNOVUGEN ONCOLOGY SDN BHDSUN PHARMACEUTICAL INDUSTRIES LTDTEVA PHARMACEUTICALS INCTORRENT PHARMACEUTICALS LTD
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.